Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.46 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25380744 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8180021 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL25380998 | 0.93 | ALDH1A1 (0.52) | ALDH1A1CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL25380995 | 0.93 | ALDH1A1 (0.52) | ALDH1A1CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL29206572 | 0.93 | ALDH1A1 (0.52) | ALDH1A1CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL27262608 | 0.91 | ALDH1A1 (0.50) | ALDH1A1CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL20500815 | 0.91 | ALDH1A1 (0.50) | ALDH1A1CHRM5CHRM1CHRM3SMN1; SMN2 | |
| Water SCHEMBL28746415 | 0.91 | ALDH1A1 (0.50) | ALDH1A1CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL25380570 | 0.86 | — | — | |
| SCHEMBL48552 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | Sea Pharmaceuticals LLC. (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2023130008-A2 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | SEA PHARMACEUTICALS LLC (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-101109899-B | Resist composition | DAICEL CHEM | 2011-08-17 | — | — | CN | disclosed |
| EP-1899452-B1 | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ENHANCED EXPRESSION OF THE FUCPIKUR OPERON | AJINOMOTO KK (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090209011-A1 | Method for Producing an L-Amino Acid Using a Bacterium of the Enterobacteriaceae Family With Enhanced Expression of the fucPIKUR Operon | AJINOMOTO CO., INC. (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-1899452-A1 | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ENHANCED EXPRESSION OF THE FUCPIKUR OPERON | Ajinomoto Co., Inc. (JP) | 2008-03-19 | — | — | EP | disclosed |
| CN-101109899-A | Resist composition | DAICEL CHEM (JP) | 2008-01-23 | — | — | CN | disclosed |
| WO-2006135075-A1 | A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE ENTEROBACTERIACEAE FAMILY WITH ENHANCED EXPRESSION OF THE FUCPIKUR OPERON | AJINOMOTO CO., INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| WO-2000049019-A2 | NOVEL EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-24 | — | — | WO | disclosed |
| US-4921860-A | Quinuclidyl- and tropanyl-pyridyl ethers as 5-HT3 receptor antagonists | JOHN WYETH AND BROTHER, LIMITED (GB) | 1990-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | GABRQ, GRIK5, CYP3A7 | ALDH1A1 501/4885CHRM5 461/4885CHRM1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.